NCT07531095

Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)

A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Tarlatamab in Combination With ZL-1310 With or Without Anti-PD-L1 in Participants With Small Cell Lung Cancer

• Status: Not Yet Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 160 (estimated)
• Sponsor: Amgen · Industry
• Sex: All
• Age: 18 Years – 99 Years
• Healthy volunteers: Not accepted

Summary

The primary objective of this trial is to evaluate the safety and tolerability of tarlatamab in combination with ZL-1310 with or without durvalumab and to determine the maximum tolerated combination dose (MTCD) and/or recommended phase 2 dose (RP2D) of ZL-1310 in combination with tarlatamab.

Conditions

• Small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	ZL-1310	ZL-1310 will be administered as an IV infusion.
DRUG	Tarlatamab	Tarlatamab will be administered as an IV infusion.
DRUG	Durvalumab	Durvalumab will be administered as an IV infusion.

Timeline

• Start date: 2026-05-05
• Primary completion: 2028-05-21
• Completion: 2031-05-21
• First posted: 2026-04-15
• Last updated: 2026-04-15

Regulatory

• FDA-regulated drug study